Revue d'éditeurNbN3 is a Medical appli for Android phones and tablets developed by inManage LTD. The latest APK version of NbN3 is 3.4 compatible with Nexus, Sumsung Galaxy, LG, Huawei and Kindle Fire mobile phones and android devices having system version 4.2 and higher. The last mod was released on 11-janv.-2022 and has google play package name il.co.inmanage.nbnomenclature. Please read the details about the appli below. Easy and fast NbN3 APK download of the android version 3.4 is available directly on ApkGain.com. NbN3 APK is the property and trademark from the developer inManage LTD. Please note that we only provide the original and free apk package installation without any modifications. Check our "safe download" sign to get the latest report from McAfee to see if the NbN3 download is completely secure. Customers who installed and used this appli gave over 53 user ratings with an average rating 3,0 of 5 stars relating to NbN3. More than 10000 people have used this appli by now. Join them now and download NbN3 appli APK directly on our ApkGain.com play market!
Description
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
Télécharger et installez libre android apk fichier Pour NbN3.
